ImmunityBio (IBRX) Gross Profit (2023 - 2026)

ImmunityBio (IBRX) has reported Gross Profit for 4 consecutive years, with $44.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 167.14% year-over-year to $44.0 million; the TTM figure through Mar 2026 stood at $140.0 million (up 349.38% YoY), while the FY2025 annual figure was $112.5 million, up 663.21% from the prior year.
• Gross Profit advanced to $44.0 million in Q1 2026 per IBRX's latest filing, from $37.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $44.0 million in Q1 2026 and bottomed at $40000.0 in Q1 2024.
• Historically, Gross Profit has averaged $14.3 million across 4 years, with a median of $6.8 million in 2024.
• Annual changes were most pronounced in 2025 — Gross Profit surged 41047.5% — and 2026, when it surged 167.14%.
• ImmunityBio's Gross Profit stood at $139000.0 in 2023, then jumped by 5333.09% to $7.6 million in 2024, then jumped by 401.89% to $37.9 million in 2025, then rose by 16.0% to $44.0 million in 2026.
• Business Quant data shows IBRX's Gross Profit at $44.0 million in Q1 2026, $37.9 million in Q4 2025, and $31.9 million in Q3 2025.